Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Brukinsa
Pharma
BeiGene's Brukinsa surpasses AZ’s Calquence in quarterly sales
CEO John Oyler compared BeiGene's potential in CLL to two other legendary Big Biotech stories—Gilead in HIV and Vertex in cystic fibrosis.
Angus Liu
Feb 27, 2025 10:56am
Should BeiGene or Legend sell itself in 2025?
Jan 9, 2025 9:15am
BeiGene pushes biomarker testing before treatment for CLL
Dec 4, 2024 6:00am
BeiGene defends Brukinsa from MSN's generic threat until 2037
Nov 19, 2024 3:55pm
BeiGene becomes BeOne Medicines in major rebrand
Nov 14, 2024 8:20am
TROP2 ADCs, Merck-Daiichi, Eisai—Fierce Pharma Asia
Aug 9, 2024 8:25am
